RNG Q1 Earnings Call: AI-Driven Portfolio Delivers Steady Growth and Margin Expansion
Office and call centre communications software provider RingCentral (NYSE:RNG) met Wall Street's revenue expectations in Q1 CY2025, with sales up 4.8% year on year to $612.1 million. The company expects next quarter's revenue to be around $617 million, close to analysts' estimates. Its non-GAAP profit of $1 per share was 4.2% above analysts' consensus estimates.
Is now the time to buy RNG? Find out in our full research report (it's free).
Revenue: $612.1 million vs analyst estimates of $610.6 million (4.8% year-on-year growth, in line)
Adjusted EPS: $1 vs analyst estimates of $0.96 (4.2% beat)
Adjusted Operating Income: $133.4 million vs analyst estimates of $129.7 million (21.8% margin, 2.8% beat)
Revenue Guidance for Q2 CY2025 is $617 million at the midpoint, roughly in line with what analysts were expecting
Management reiterated its full-year Adjusted EPS guidance of $4.20 at the midpoint
Market Capitalization: $2.47 billion
RingCentral's first quarter results were shaped by continued adoption of its AI-led multi-product strategy and growing customer demand in core voice communications. CEO Vlad Shmunis emphasized the company's progress in shifting traditional communications to cloud-based solutions, noting, "The early results of these new products are promising." Management highlighted strong momentum in products like RingCX and RingSense, as well as successful expansion within small business and global service provider (GSP) customer segments. President and COO Kira Makagon cited improved operational efficiency and customer outcomes, with AI tools helping to reduce manual work and drive business value for clients across healthcare, financial services, and retail. The company attributed margin improvements to disciplined sales and marketing spending and reported progress in free cash flow generation and debt reduction.
Looking forward, RingCentral's outlook is anchored by ongoing investment in AI-powered solutions, expansion of its product suite, and a focus on profitable growth. CFO Abhey Lamba confirmed that the company intends to maintain operating profitability and free cash flow improvement, stating, "We are committed to further driving operational efficiencies resulting in margin expansion while enabling us to invest in growth opportunities." Management signaled cautious optimism given macroeconomic uncertainties, such as tariffs and shifting customer spending patterns, but expects continued demand for cost-saving AI products. CEO Vlad Shmunis added, "The next phase in our growth will be driven by leveraging AI throughout our growing portfolio with increased addressable market and wallet share."
Management attributed the quarter's performance to adoption of new AI-enabled products, rising engagement among small businesses and GSP partners, and operational efficiencies that supported margin gains.
AI product traction: The company's new AI-powered products, including RingCX (cloud contact center), RingSense (AI insights and coaching), and AIR (AI phone agent), saw rapid early adoption, especially among small businesses and GSPs. Management reported over 1,000 AIR customers and strong sequential growth in RingSense usage, with AI tools cited as drivers of measurable cost savings and productivity gains for clients.
Small business momentum: ARR from customers with fewer than 100 employees grew by double digits, reaching a two-year high. These clients, often in healthcare, retail, and financial services, are adopting voice-centric AI products for customer engagement and operational efficiency, delivering higher average revenue per user and faster payback for RingCentral.
GSP partnerships expanding: Global service providers accounted for over 10% of ARR, with double-digit growth and efficient customer acquisition. Major partners like AT&T, Vodafone, and Cox Communications are now reselling RingCentral's AI-powered solutions, extending reach in North America and international markets.
Enterprise and channel strengths: Larger enterprises continue to adopt RingCentral, drawn to its integrations with platforms such as Microsoft Teams and Salesforce. Over half of $1 million-plus TCV deals in Q1 included multiple RingCentral products, signaling success in cross-selling and up-selling to existing accounts.
Operational discipline: Operating margin improvement stemmed from efficiencies in sales, marketing, and internal use of AI, which has increased productivity in customer support, sales outreach, and product development. Record free cash flow enabled debt reduction and share repurchases, supporting a stronger balance sheet.
RingCentral's forward guidance rests on expanding its AI-first portfolio, disciplined cost management, and continued growth in core markets despite macroeconomic uncertainties.
AI-led product expansion: Management expects ongoing adoption of new AI-powered offerings—such as AIR and RingCX—to drive higher average revenue per user and open new customer segments. These products are positioned as cost-saving and productivity-boosting solutions for both existing and new clients.
Go-to-market leverage: The company plans to deepen relationships with GSPs and channel partners, using these alliances to efficiently access international markets and supplement direct sales, particularly as cloud adoption accelerates among businesses replacing legacy systems.
Macro environment monitoring: While not seeing immediate headwinds, management remains cautious regarding tariffs, interest rates, and broader economic conditions. The company aims to maintain flexibility in its approach, emphasizing prudent financial management and readiness to adjust strategy if customer demand or deal cycles shift.
In the coming quarters, StockStory analysts will be watching (1) sustained adoption and revenue contribution from AI-powered products like AIR and RingCX, (2) the pace of expansion among small business and GSP customer segments, and (3) progress toward free cash flow and margin targets through operational efficiency. The ability to maintain growth despite macroeconomic fluctuations will also be an important marker of execution.
RingCentral currently trades at a forward price-to-sales ratio of 1×. In the wake of earnings, is it a buy or sell? See for yourself in our full research report (it's free).
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
4 hours ago
- Yahoo
Retail Traders Just Sent This AI Health Stock Soaring 60%
Oscar Health (NYSE:OSCR) has exploded nearly 60% this week, adding close to $2 billion in market cap without a single press release or earnings update. The real catalyst? A retail trading frenzy. OSCR became one of the most-mentioned names on r/WallStreetBets, and trading volume followed suitnearly 50 million shares changed hands on Wednesday alone, the second-highest in the company's history. Options activity lit up as well, with call volumes hitting a record 152,414 that day, and another 95,000 contracts moving by Friday morning, nearly triple the norm. Beneath the surge is a company with serious revenue momentumup 48% in 2023 and 57% in 2024. Adjusted earnings per share reached $0.92 in Q1 2025. But Oscar isn't just selling insuranceit's selling a story. Management brands the company as a health-tech platform, powered by AI and run on what it calls a continuous hackathon model. That pitch, familiar to anyone who's followed high-multiple tech names, is likely helping Oscar catch a more generous valuation than traditional insurers. Retail traders appear to be buying into that promise. Another factor? The Kushner connection. Joshua Kushner, vice chairman of Oscar's board and brother to Jared Kushner, has remained a prominent name in business and politics alike. That visibility might be adding an extra layer of speculation to the mix. But for now, the stock's movement is being driven more by momentum than fundamentals. Oscar is just $3 shy of its all-time highand the retail crowd seems determined to carry it the rest of the way. This article first appeared on GuruFocus.
Yahoo
4 hours ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
